Bicycle Therapeutics Executives Sell Shares at $6.45-$6.8/Share in January 2026.

Bicycle Therapeutics PLC (BCYC) has recently disclosed that several of its executives have engaged in stock transactions. Chief Product and Supply Chain Officer Michael Charles Ferguson sold 2,367 shares at $6.45 per share on January 5, 2026, and 2,827 shares at $6.8 per share on January 2, 2026. Director and Chief Executive Officer Kevin Lee sold 10,889 shares at $6.46 per share on January 5, 2026, and 10,325 shares at $6.8 per share on January 2, 2026. Chief Operating Officer Alistair Milnes sold 3,416 shares at $6.46 per share on January 5, 2026, and 3,244 shares at $6.8 per share on January 2, 2026. Chief Technology Officer Michael Skynner sold 3,266 shares at $6.46 per share on January 5, 2026, and 3,045 shares at $6.8 per share on January 2, 2026. Chief Accounting Officer Travis Alvin Thompson sold 1,115 shares at $6.45 per share on January 5, 2026, and 1,317 shares at $6.8 per share on January 2, 2026. Chief Financial Officer Alethia Young sold 1,878 shares at $6.54 per share on January 5, 2026, and 3,289 shares at $6.8 per share on January 2, 2026, as well as an additional 2,456 shares at $6.45 per share on January 5, 2026.